Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb Company (NYSE:BMY) to $57 from$51 and kept a Neutral rating on the shares. Bristol-Myers Squibb Company (NYSE:BMY) presents a measured balance between risk and reward. The stock offers a 4.6% dividend yield, and the payout ratio sits near 85%. ...